It may be too little too late. But now the FDA has signed off on the use of transvaginal ultrasound as a means of ensuring the proper placement of the Essure permanent birth control device within three months of its insertion.
Bayer has said it can pump an extra $400 million in revenue out of the OTC portfolio it acquired from Merck last year. And with that target in mind, new launches are on the agenda.
Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.
Whether animal health leader Zoetis receives any more buyout offers after Valeant's reported approach remains to be seen. But if it does, Bayer's leaders insist a competing bid won't be coming from them.
For a while now, Bayer and Johnson & Johnson's Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.
Japan's Pharmaceuticals and Medical Devices Agency approved Bayer's Eylea for the treatment of diabetes-related visual impairment, the company said in a release June 26.
The U.S. Food and Drug Administration has further formalized its ongoing review of the controversial Essure permanent birth control implant from Bayer.
Bayer is gearing up to spend more than ever before on R&D this year, CEO Marijn Dekkers said, investing in innovation with hopes of pushing some promising therapies onto the market.
The last day for most of 120 employees of a Bayer Animal Health operation in Missouri will be June 24. The company Wednesday confirmed the plant will close at the end of next week, less than a month after Bayer CEO Marijn Dekkers indicated he wanted to build Bayer's animal health business.
German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.